Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis.
Missed epidemics and missing links: international birth cohort trends in multiple sclerosis.
Silencing IFN-γ Binding/Signaling in Astrocytes versus Microglia Leads to Opposite Effects on Central Nervous System Autoimmunity.
B lymphocytes in neuromyelitis optica.
Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis.
Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis.
Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity.
Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.
Multiple sclerosis.
What is microglia neurotoxicity (Not)?
JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants.
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice.
Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon-beta 1a: Case Report.
Seronegative neuromyelitis optica presenting with life-threatening respiratory failure.
Bifacial weakness with paresthesias: Serial nerve conduction studies indicate diffuse demyelinating neuropathy.
SIRT1 Deficiency in Microglia Contributes to Cognitive Decline in Aging and Neurodegeneration via Epigenetic Regulation of IL-1β.
Remyelination by Resident Oligodendrocyte Precursor Cells in a Xenopus laevis Inducible Model of Demyelination.
Towards therapeutic applications of arthropod venom k(+)-channel blockers in CNS neurologic diseases involving memory acquisition and storage.
Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13.
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes.
Encephalitis followed by optic neuritis: a case report and review of literature.
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis.
Prediction of risk of fracture in the tibia due to altered bone mineral density distribution resulting from disuse: A finite element study.
Effects of Bacille Calmette-GuÉrin after the first demyelinating event in the CNS.
Models for treating depression in specialty medical settings: a narrative review.
Pages
« first
‹ previous
…
240
241
242
243
244
245
246
247
248
…
next ›
last »